



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/758335-Conf. #6410
		Filing Date	January 15, 2004
		First Named Inventor	Seth J. ORLOW
		Art Unit	1614
		Examiner Name	J. D. Anderson
Total Number of Pages in This Submission	4	Attorney Docket Number	PFI-016CIPDIV/71369.368US1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature			
Printed name	Ann-Louise Kerner, Ph.D.		
Date	April 20, 2006	Reg. No.	33,523

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 20, 2006

Signature:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 10/758,335 Art Unit: 1614
Applicant: Orlow *et al.* Examiner: James D. Anderson
Date Filed: January 15, 2004 Conf. No. 6410
Docket No. 71369.368 and PFI-016CIPDV Cust. No. 23483
Title: METHODS AND COMPOSITIONS THAT AFFECT MELANOGENESIS

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

04/20/2006

Date of Mail Deposit

Rochelle Capobianco

Rochelle Capobianco

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In the Restriction Requirement mailed on *April 3, 2006*, the Examiner restricted the pending claims of the above application into the following five Groups:

Group I: Claims 1-17, 32-36 and 38-43, drawn to a method of screening for compounds that inhibit melanogenesis comprising treating cells expressing a tyrosine-encoding gene with a test compound that inhibits Melano-genesis. (Claims 32-36 and 38-43 will be examined with this Group to the extent the method reads on inhibiting P protein.)

Group II: Claims 18-34 and 37-43, drawn to a method of screening for compounds that increase melanogenesis comprising treating cells expressing a tyrosine-encoding gene with a test compound that increases Melanogenesis. (Claims 32-34 and 37-43 will be examined with this Group to the extent the method reads on increasing P protein.)

Group III: **Claims 44-56**, drawn to methods of decreasing melanin production in a melanocyte comprising contacting the melanocyte with an effective amount of a compound that effects an alteration in late endosomal/lyso-somal trafficking and **Claims 57-69**, drawn to a method of reducing skin pigmentation comprising contacting skin with a pharmaceutically effective amount of a compound that effects an alteration in endosomal/lysosomal trafficking.

Group IV: **Claims 70-73**, drawn to a method of activating melanogenesis comprising contacting a melanocyte with diminished or absent P protein activity with a compound that inhibits ATPase.

Group V: **Claims 74-77**, drawn to a method of treating tyrosinase-positive, oculocutaneous albinism in an individual in need thereof comprising contacting the skin of the individual with a pharmaceutically effective amount of a compound that inhibits ATPase.

In response to the Restriction Requirement, Applicants elect the claims of **Group III**, namely **claims 44-56 and 57-69**.

Appl. No.: 10/758,335
Response dated April 20, 2006
Reply to Office Action dated April 3, 2006

CONCLUSION

Claims 1-77 remain pending in the instant application.

No fees are believed to be due in connection with this communication; however, if any fees are due, please charge the requisite fees to Deposit Account No. 08-0219.

If the Examiner has any questions, he is requested to contact the undersigned at the number listed below.

Respectfully submitted,

Date: April 20, 2006

Ann-Louise Kerner

Ann-Louise Kerner, Ph.D.
Reg. No. 33,523
Attorney/Agent for Applicants

WILMER CUTLER PICKERING HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6192 (Telephone)
(617) 526-5000 (Facsimile)